[{"id":"8e400406-6f6a-4f41-824d-61725c09b480","acronym":"CICPD","url":"https://clinicaltrials.gov/study/NCT04381741","created_at":"2021-01-18T21:09:36.209Z","updated_at":"2024-07-02T16:35:56.413Z","phase":"Phase 1","brief_title":"CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04381741 - CICPD","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CD20 • CD19 • PD-1 • CCL19 • IL7","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19 • PD-1 • CCL19 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • CD19-7×19 CAR-T"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 24","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-06"},{"id":"36dae252-34db-4379-9046-72e155c4512d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04833504","created_at":"2021-04-06T11:55:29.016Z","updated_at":"2024-07-02T16:36:32.311Z","phase":"","brief_title":"Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04833504","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" CCL19 • IL7","pipe":"","alterations":" ","tags":["CCL19 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19-7×19 CAR-T"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2021-04-06"}]